STOCKHOLM: Inify Laboratories announces the addition of specialized medical competence to the company’s management team and organization. “We warmly welcome Dr. Claes Lind to the role as Chief Medical Officer (CMO). His impressive background in clinical diagnostics and education fits us perfectly. He will play an instrumental role in our establishment and expansion phase. The fact that we can attract such key competences to the company is a stamp of quality for our strategy and concept,” says Fredrik Palm.
Dr. Lindh will join Inify Laboratories in September 2022 as Chief Medical Officer. He holds a M.D. as well as a Ph.D. in the field of prostate cancer pathology from Karolinska Institute, and has 14 years of experience in diagnostic pathology. He has worked as an expert pathologist in clinical diagnostics, cancer research, and higher education. Before joining Inify Laboratories, he acted as a senior consultant pathologist in Urological and Gynecological pathology at Karolinska University Hospital. He has collaborated in various translational research projects related to urological oncology.
Dr Lindh is also an experienced educator in pathology for bothmedical professionals and students.
“The vision of Inify Laboratories- to take diagnostic pathology to a new level by applying cutting-edge technology – represents an important milestone in the history of pathology. Toparticipate in making the vision reality is truly thrilling,” says Dr. Claes Lindh.
“The CMO is a cornerstone recruitment for Inify, and a perfect match with our targeted profile,” says CEO Fredrik Palm.
Inify Laboratories is currently building and establishing an ultramodern laboratory that will provide cancer diagnostics within histopathology. Designed from scratch, it uses a fully digital, standardized and AI-supported workflow to optimize quality and shorten response times, initially within prostate cancer.
The first laboratory, located at Campus Solna Sweden, is estimated to start offering services to both public and private healthcare providers before summer 2023.
The company originates from ContextVision, with nearly 40 years of experience within digital imaging for medical applications, and became independent through a spin-off in February 2022.
The company, based in Sweden, is listed on Euronext Growth Oslo under the ticker INIFY.